COMP

COMP

COMP Molekülinformation

Molecule Name
Sodium channel protein type VIII alpha subunit
Molekülalias
COMP,TSP5,EDM1,EPD1,MED,PSACH,THBS5
Drug Development Progress
Anzahl der klinischen Arzneimittel4
Anzahl der inverkehr gebrachten Arzneimittel1
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
Sodium Channel, Voltage Gated, Type VIII Alpha Subunit,Voltage-Gated Sodium Channel Type VIII Alpha Protein,HNa6/Scn8a Voltage-Gated Sodium Channel,CERIII,EIEE13,Nav1.6,BFIS5,NaCh6,CIAT,PN4,NAV1.6 Voltage-Gated Sodium Channel,MYOCL2,Sodium channel protein type 8 subunit alpha,Sodium channel protein type VIII subunit alpha,MED,SCN8A,Sodium Voltage-Gated Channel Alpha Subunit 8,Sodium Channel, Voltage Gated, Type VIII, Alpha Subunit,Voltage-Gated Sodium Channel Subunit Alpha Nav1.6,Sodium Channel, Voltage Gated, Type VIII, Alpha Polypeptide
Molekülhintergrund
Cartilage oligomeric matrix protein (COMP) is also known as Thrombospondin-5 (TSP5), EDM1, EPD1, MED, PSACH, THBS5, which belongs to the thrombospondin family. COMP / TSP5 contains 4 EGF-like domains, 1 TSP C-terminal (TSPC) domain, 8 TSP type-3 repeats. Abundantly expressed in the chondrocyte extracellular matrix, and is also found in bone, tendon, ligament and synovium and blood vessels. COMP may play a role in the structural integrity of cartilage via its interaction with other extracellular matrix proteins such as the collagens and fibronectin. COMP can mediate the interaction of chondrocytes with the cartilage extracellular matrix through interaction with cell surface integrin receptors. Thrombospondin-5 could play a role in the pathogenesis of osteoarthritis. COMP is a marker of cartilage turnover.

COMP Produktliste

Species
  • Human(1)
Tag
  • His Tag(1)
Host
  • HEK293(1)
Conjugate
  • Unconjugated(1)
Grade
  • RUO(1)
Low Endotoxin
  • No(1)
MoleculeCat. No.Product NameArtHostStructurePurityActivitySize&PriceAdd to Cart
COMP
Human COMP / TSP5 Protein, His Tag
Human
HEK293
SDS-PAGE
CELL BASE

$285.00

100ug
You Have Viewed 1-1 Of 1 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
PRAX-562PRAX-562Phase 3 ClinicalPraxis Precision Medicines
Brain Diseases; Epilepsy
Details
XEN-901NBI-921352; XEN-901Phase 2 ClinicalXenon Pharma
Epilepsies, Partial; Brain Diseases; Epilepsy
Details
PRAX-330GS-458967; GS-967; PRAX-330Phase 1 ClinicalPraxis Precision Medicines Inc
Epilepsy
Details
NBI-355NBI-355Phase 1 ClinicalNeurocrine Biosciences Inc
Epilepsy
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Pirmenol HydrochlorideCI-845ApprovedSumitomo Dainippon, Pfizer IncPimavar, PimenolJapanArrhythmias, Cardiacnull1994-01-01
Arrhythmias, Cardiac
Details
Customer Reviews